By Tom Winnifrith, The Sheriff of AIM | Saturday 26 November 2016
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
Yesterday shares in Advanced Oncotherapy (AVO) plunged after it fessed up that a critical deal worth up to $120 million with a Chinese entity had encountered problems. Those who backed a big fundraise just weeks ago are already 26% down. But the incident begs massive questions about the timeline of disclosure and RNS statements that appear to be utterly untrue. I have written to the FCA & AIM Regulation, as this appears to be market abuse, outlining my very specific concerns and demanding an urgent enquiry and, if appropriate, that sanction be taken against those responsible. The letter is below:
Already a subscriber? Click here to sign in
This area of the ShareProphets.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ShareProphets.com. ShareProphets.com does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ShareProphets.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ShareProphets.com and is not intended to be relied upon by users in making (or refraining from making) any investment decisions.
Search ShareProphets |
Stock market news |
Recent Comments |
Site by Everywhen